Executive Director, Global Value, Access & Pricing

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

This position will lead the development and execution of global market access and pricing strategies for one of the key disease areas, and work with regions to build resources to support optimal access for pipeline assets. The role ensures that the CDPs and asset positioning is developed with an access strategy and pricing reimbursement perspective that is aligned across all regions.  This individual will collaborate closely with the Health Economics and Outcomes Research (HEOR), Medical and Region Market Access teams to align global and regional initiatives and play a key role in business development access strategies.  In addition, define the product’s value narrative/Global Value dossier planning and development, guide pricing and reimbursement including net pricing corridors, optimal country launch sequence and ensure sustainable access in key global markets. Reporting to the VP, Global Value, Access and Pricing, this role will work cross-functionally to influence long-term growth, patient impact, and company valuation.

Responsibilities:

Global Value, Access & Pricing Strategy

• Formulate and define asset and disease area pricing and reimbursement strategies to support optimal access and reimbursement outcomes across all target regions. This includes asset global pricing architecture and launch sequencing strategy to develop net price corridors, reference pricing and value-based designs.

• Craft a differentiated global value proposition and oversee the development of the Global Value Dossier (GVD) and payer negotiation materials.

• Work closely with members of the Disease Area Strategy teams to help shape priority clinical development plans and combinations with both RevMed and oncology combination therapy opportunities.

• Design and implement strategic plans to support clinical development programs to ensure study designs, endpoints, and analyses generate the evidence needed for payer and HTA submissions including seeking systematic HTA advice.

• Identify and assess global market access risks and opportunities, integrating them into product strategies and reflecting them in Target Product Profiles (TPPs).

• Partner with Clinical Development and Regulatory Affairs to incorporate payer and patient relevant evidence into clinical development strategies.

• Collaborate closely with the HEOR team to ensure alignment between market access needs and health economic research plans for pipeline assets.

• Engage with Regions to incorporate payer, policy insights and global trends into product access strategy.

Launch Readiness & Market Engagement

• Lead global payer research and early engagement/advice from key HTA bodies (e.g., G-BA, NICE, HAS, AIFA, Chuikyo).

• Develop and maintain strong business relationships with key functions responsible for value proposition enablement with a focus on Clinical, Commercial, Regulatory, Medical Affairs, and HEOR stakeholders.

• Prepare and submit reimbursement and HTA dossiers in priority markets with clear alignment to clinical and economic evidence plans.

Cross-Functional and Team Leadership

• Partner with Medical Affairs, HEOR, Regulatory, and Clinical to align evidence generation with access and reimbursement needs.

• Build and lead a high-performing Global Market Access team and coordinate closely with regional leads and country affiliates.

• Serve as a key leader within the global launch team, actively contributing to go-to-market planning, demand forecasting, and gross-to-net-scenario modeling.

Policy, Risk & External Engagement

• Monitor and address global policy risks (e.g., IRA, international reference pricing, transparency laws).

• Represent the company externally with payers, HTA bodies, trade associations, and policy groups, helping shape access environments.

• Coordinate with the U.S. region to align on policy and legislation risks that could impact life cycle management pricing corridors.

Required Skills, Experience & Education:

• Bachelor’s degree required; advanced degree in Pharmacy, Health Economics, Public Health, Life Sciences, or Business preferred (e.g., PharmD, PhD, MBA).

• Minimum 15+ years of progressive leadership in market access, pricing, and reimbursement within the biopharma industry.

• Demonstrated success launching a first-in-class or specialty therapy in the U.S. and multiple ex-U.S. markets (especially Germany, France, and Japan).

• Demonstrating the ability to build a new capability and framework to support a Global Market Access commercialization strategy.

• Deep understanding of global payer systems and HTA processes, including AMNOG, Chuikyo, NICE, and other EU frameworks.

• Experience designing and implementing global pricing strategy, including value-based pricing, launch sequencing, and reference pricing mitigation.

• Proven ability to work cross-functionally and influence executive leadership in a dynamic, resource-constrained, early-stage company.

Preferred Skills:

• Prior experience with Ex-U.S. and U.S. legislation and public policies that impact Global and regional decisions (U.S. IRA, MFN, EU regulations etc.)

• Familiarity with rare disease, or oncology product launches.

• Experience working with external vendors, consultants, and access agencies to develop payer research, modeling, and dossier development.

• Strong executive presence, with the ability to clearly articulate complex value stories to both internal and external stakeholders.

• Experience building or scaling global market access functions in a pre-commercial or newly commercial biotech company. 

  #LI-DNI